The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-center phase III study of carboplatin/paclitaxel versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer
 
Shinichi Toyooka
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien; Daiichi Sankyo; Johnson & Johnson; Otsuka; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Covidien (Inst); Dainippon Sumitomo Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Norihito Okumura
Honoraria - Taiho Pharmaceutical
 
Hiroshige Nakamura
No Relationships to Disclose
 
Masao Nakata
No Relationships to Disclose
 
Motohiro Yamashita
No Relationships to Disclose
 
Hirohito Tada
No Relationships to Disclose
 
Shinsuke Kajiwara
No Relationships to Disclose
 
Naoki Watanabe
No Relationships to Disclose
 
Morihito Okada
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Keitaro Matsuo
No Relationships to Disclose
 
Motoi Aoe
No Relationships to Disclose
 
Katsuyuki Hotta
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Lilly Japan
Research Funding - Chugai Pharma; Lilly Japan; MSD
Travel, Accommodations, Expenses - AstraZeneca Japan
 
Junichi Sakamoto
Honoraria - Tsumura & Co.
Consulting or Advisory Role - Takeda
 
Shinichiro Miyoshi
No Relationships to Disclose
 
Hiroshi Date
Honoraria - Taiho Pharmaceutical